Sökning: WFRF:(Korelitz Burton I.) >
Effects of Vedolizu...
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
-
- Fleisher, Mark (författare)
- Borland-Groover Clinic
-
- Marsal, Jan (författare)
- Lund University,Lunds universitet,Adaptivt immunförsvar,Forskargrupper vid Lunds universitet,Medicin/akutsjukvård, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Gastro,Adaptive Immunity,Lund University Research Groups,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Lee, Scott D. (författare)
- University of Washington
-
visa fler...
-
- Frado, Laura E. (författare)
- Mount Sinai Hospital
-
- Parian, Alyssa (författare)
- Johns Hopkins Hospital
-
- Korelitz, Burton I. (författare)
- Lenox Hill Hospital
-
- Feagan, Brian G. (författare)
- University of Western Ontario
-
visa färre...
-
(creator_code:org_t)
- 2018-02-26
- 2018
- Engelska.
-
Ingår i: Digestive Diseases and Sciences. - : Springer Science and Business Media LLC. - 0163-2116 .- 1573-2568. ; 63:4, s. 825-833
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://link.springe...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy. Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn’s disease. Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Nyckelord
- Crohn’s disease
- Extraintestinal manifestations
- Inflammatory bowel disease
- Ulcerative colitis
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas